trending Market Intelligence /marketintelligence/en/news-insights/trending/a9G9KzWAI_HqkunHOGoUOw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

GHO Capital acquires early phase drug developer from Mentha Capital

Blog

Banking Essentials Newsletter - February Edition, Part 2

Podcasts

StreetTalk – Episode 74: Investor sees legs in strong credit performance, US bank stock rally

Blog

Street Talk – Episode 74: Investor sees legs in strong credit performance, US bank stock rally

Blog

The Evolution of ESG Factors in Credit Risk Assessment: Environmental Issues


GHO Capital acquires early phase drug developer from Mentha Capital

Specialist healthcare investment adviser GHO Capital Partners LLP acquired Ardena Holding NV and its existing management from Amsterdam-based Mentha Capital BV.

Alvarez & Marsal, Deloitte, Sidley Austin LLP, Loyens & Loeff NV, CIL Management Consultants, E&Y’s Life Sciences Corporate Finance Team, Matrix Global Services Ltd., AON, ERM and Saola Healthcare Partners advised GHO on the transaction.

William Blair, Deloitte, LEK Consulting, deBreij, Schoups, Delphi, Ellex, CorporateWise, van Doorne and ERM advised Ardena.

GHO recently announced the close of their second specialist healthcare private equity fund at its hard cap of €975 million and last year completed investments in Sterling Pharma and BioAgilytix, as well as exits from Quotient Sciences and Caprion Biosciences.

Belgium-headquartered Ardena is a multiservice contract development and manufacturing organization focused on early phase drug development.